AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer
January 06 2020 - 7:00AM
Business Wire
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of
Erick Lucera as chief financial officer. Mr. Lucera will be
responsible for managing all aspects of the Company’s financial and
accounting functions.
“It is a pleasure to welcome Erick to the AVEO team,” said
Michael Bailey, president and chief executive officer of AVEO.
“With a proven track record of success in a range of senior
executive roles at multiple biopharmaceutical and medical
technology companies, his experience will be invaluable as we
continue to pursue our goal of unlocking the full potential of
tivozanib and advance the remainder of our pipeline candidates. I
look forward to leveraging his insights as we work toward becoming
a fully integrated biopharmaceutical company.”
“With a New Drug Application filing for tivozanib expected in
the first quarter of 2020, I believe AVEO is well-positioned to
deliver on its goal of bringing novel, effective cancer therapies
to patients with high unmet need,” said Mr. Lucera. “I look forward
to working alongside an accomplished leadership team and to
contributing to the Company’s success.”
Mr. Lucera brings to AVEO over twenty years of financial,
operational, and investment experience in the biotechnology and
medical device industries. He most recently served as chief
financial officer of Valeritas, a publicly traded commercial-stage
medical technology company focused on developing solutions for
people with diabetes, where he led the company through multiple
public offerings. Prior to Valeritas, Mr. Lucera served as the
chief financial officer, treasurer, and secretary of Viventia Bio
(acquired by Eleven Biotherapeutics, Inc., now Sesen Bio), a
biotechnology company focused on developing targeted protein
therapeutics for the treatment of cancer. He also previously served
as vice president, corporate development at Aratana Therapeutics, a
veterinary biopharmaceutical company, where he helped grow the
company’s product pipeline through a series of acquisitions and
in-licensing transactions financed through five public and private
offerings of nearly $250 million in aggregate. Previously, Mr.
Lucera was vice president, corporate development at Sunshine Heart
(now CHF Solution), a medical device manufacturer.
Prior to Sunshine Heart, Mr. Lucera spent over 15 years in
investment management as a healthcare analyst at Eaton Vance, the
portfolio manager of the Triathlon Life Sciences Fund at Intrepid
Capital, and as head of the healthcare research team at
Independence Investments. He began his career as a staff auditor
and accountant at Price Waterhouse & Co. (now PwC). Mr. Lucera
holds a CPH from Harvard University, an MS from Boston College, an
MBA from Indiana University Bloomington, and a BS in accounting
from the University of Delaware. Mr. Lucera holds CFA, CMA, and CPA
designations.
About AVEO
AVEO Pharmaceuticals is a biopharmaceutical company seeking to
advance targeted medicines for oncology and other unmet medical
needs. The Company’s lead candidate is tivozanib, a potent,
selective, long half-life inhibitor of vascular endothelial growth
factor 1, 2 and, 3 receptors, which AVEO is seeking to develop and
commercialize in North America as a treatment for renal cell
carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers.
Tivozanib (FOTIVDA®) is approved by the European Commission for the
treatment of adult patients with advanced RCC in the European Union
plus Norway, New Zealand and Iceland. AVEO is leveraging or seeks
to leverage partnerships to develop and commercialize its pipeline
of products and product candidates, including tivozanib in oncology
and other indications in various geographies, and ficlatuzumab (HGF
MAb) in head and neck cancer, pancreatic cancer and acute myeloid
leukemia. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3
MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) drug candidates
being developed for various oncology indications.
For more information, please visit the Company’s website at
www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. The words
“anticipate,” “believe,” “expect,” “intend,” “may,” “plan,”
“potential,” “could,” “should,” “would,” “seek,” “look forward,”
“advance,” “goal,” “strategy,” or the negative of these terms or
other similar expressions, are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include,
among others, statements about: AVEO’s plans to submit a New Drug
Application for tivozanib in the first quarter of 2020; the
potential for tivozanib as a treatment option for patients with
relapsed/refractory or advanced RCC; the potential efficacy,
safety, and tolerability of tivozanib, both as a stand-alone drug
candidate and in combination with other therapies in several
indications; AVEO’s plans and strategies for commercialization of
tivozanib in the United States and Europe; and AVEO’s strategy,
prospects, plans and objectives for its product candidates and for
the Company generally. AVEO has based its expectations and
estimates on assumptions that may prove to be incorrect. As a
result, readers are cautioned not to place undue reliance on these
expectations and estimates. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements that AVEO makes due to a number of
important factors, including risks relating to: AVEO’s ability, and
the ability of its licensees, to demonstrate to the satisfaction of
applicable regulatory agencies such as the FDA the safety, efficacy
and clinically meaningful benefit of AVEO’s product candidates,
including, in particular, tivozanib and ficlatuzumab; AVEO’s
ability to successfully file an NDA for tivozanib; and AVEO’s
ability to enter into and maintain its third party collaboration
and license agreements, and its ability, and the ability of its
strategic partners, to achieve development and commercialization
objectives under these arrangements. AVEO faces other risks
relating to its business as well, including risks relating to the
timing and costs of seeking and obtaining regulatory approval;
AVEO’s and its collaborators’ ability to successfully enroll and
complete clinical trials; AVEO’s ability to maintain compliance
with regulatory requirements applicable to its product candidates;
AVEO’s ability to obtain and maintain adequate protection for
intellectual property rights relating to its product candidates;
AVEO’s ability to successfully implement its strategic plans;
AVEO’s ability to raise the substantial additional funds required
to achieve its goals, including those goals pertaining to the
development and commercialization of tivozanib; unplanned capital
requirements; adverse general economic and industry conditions;
competitive factors; and those risks discussed in the sections
titled “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations—Liquidity and Capital
Resources” included in AVEO’s quarterly and annual reports on file
with the Securities and Exchange Commission (SEC) and in other
filings that AVEO makes with the SEC. The forward-looking
statements in this press release represent AVEO’s views as of the
date of this press release, and subsequent events and developments
may cause its views to change. While AVEO may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as
representing AVEO's views as of any date other than the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200106005325/en/
AVEO Contact: David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Apr 2023 to Apr 2024